MedCanHub: a platform developed by Cellen aimed at reducing barriers of access to unlicensed cannabis-based medicinal products during the COVID-19 pandemic.

Lim Zhen Zong,Mala Mawkin,Haggai Sharon,Michael Barnes,Panagiotis Pardalidis,Sarah Marten, Giancarlo Camilleri,Benjamin Viaris de Lesegno

Clinical medicine (London, England)（2021）

引用 1|浏览1

暂无评分

摘要

Unlicensed cannabis-based medicinal products (UCBPMs) were reclassified from Schedule 1 to Schedule 2 in 2018 in the UK, allowing doctors on the Specialist Register of the General Medical Council to legally issue prescriptions for UCBPMs.[1,2][1] However, there has been evidence showing that

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要